Omega Therapeutics
About
What does Omega Therapeutics do?
Omega Therapeutics is a biotechnology company focused on developing a novel class of therapeutics called Epigenomic Controllers (ECs). These ECs are designed to precisely modulate gene expression by targeting specific epigenetic marks, offering a new approach to treating a wide range of diseases.
Where is Omega Therapeutics headquartered?
Omega Therapeutics is headquartered in Cambridge, United States.
When was Omega Therapeutics founded?
Omega Therapeutics was founded in 2017.
What industry does Omega Therapeutics operate in?
Omega Therapeutics operates in Biotech, Drug Discovery, Genomics, Epigenetic Reprogramming, Precision Medicine, Therapeutics.
What is Omega Therapeutics's current status?
Omega Therapeutics's current operating status is: Inactive.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
AI-powered platform for personalized health and longevity.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 2 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.